Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)

Historical Holders from Q4 2021 to Q3 2025

Symbol
TRDA on Nasdaq
CUSIP
29384C108
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
38.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
28.4M
Holdings value
$165M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
113
Number of buys
71
Number of sells
-44
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
5AM Ventures V, L.P. 10.8% $25.5M 4.12M Kush Parmar Nov 14, 2025
ROCHE FINANCE LTD 6.9% $23M 2.57M Roche Finance Ltd Dec 31, 2024
BlackRock, Inc. 5.3% $17.7M 1.97M BlackRock, Inc. Dec 31, 2024
TCG Crossover GP I, LLC 5% $11.8M 1.92M TCG Crossover GP I, LLC Nov 19, 2025
JANUS HENDERSON GROUP PLC 4% -26.7% $9.96M -$3.93M 1.52M -28.3% JANUS HENDERSON GROUP PLC Jun 30, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.9% -84.3% $2.09M -$12.8M 361K -86% T. Rowe Price Associates, Inc. Sep 30, 2025

Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 28.4M $165M -$9.41M $5.80 113
2025 Q2 29.6M $199M -$4.88M $6.72 105
2025 Q1 30.2M $275M -$4.48M $9.04 110
2024 Q4 30.6M $530M +$9.63M $17.29 102
2024 Q3 30.1M $481M +$6.08M $15.98 98
2024 Q2 29.7M $423M +$52.1M $14.25 82
2024 Q1 26M $369M -$3.77M $14.17 76
2023 Q4 26.3M $397M +$3.49M $15.09 62
2023 Q3 26M $411M +$4.52M $15.80 55
2023 Q2 25.8M $390M +$13.3M $15.14 56
2023 Q1 24.9M $361M +$2.71M $14.50 53
2022 Q4 24.7M $334M +$2.43M $13.52 46
2022 Q3 24.5M $386M -$2.73M $15.76 33
2022 Q2 24.8M $302M -$12.9M $12.18 35
2022 Q1 25.9M $243M +$2.26M $9.39 48
2021 Q4 24.9M $425M +$414M $17.12 45